• Wind Tre and iliad form Zefiro Net S.r.l., a 50:50 joint venture, to connect the less densely populated areas of Italy.

  • Watsons opens its 1,000th store in Manila, Philippines, adding to a total of over 8,000 stores
    across 15 markets in Asia, Europe and the Middle East.

  • Hutchison Ports announces a total investment of approximately US$700 million in two Egyptian port projects, including Ain Sokhna Port and B100, a new container terminal in the Port of Alexandria.

  • Watsons strengthens its sustainability commitment with over 9,000 Sustainable Choices products.

  • CKHGT and Vodafone Group announce agreements to combine their UK telecommunications businesses. The value-creating transaction is described to be “great for customers, great for the country and great for competition”.

  • Hutchison Ports and King Salman Energy Park sign a concession agreement to develop a dry port and bonded logistics zone in the Eastern Province of Saudi Arabia.

  • AS Watson Group and Amorepacific Group sign an agreement to bring a wide range of Korean beauty products and skincare brands to customers in Asia.

  • The Hong Kong Offshore LNG Terminal, jointly developed by HK Electric and CLP Power, commences commercial operation. The terminal gives both companies direct access to international LNG markets and provides a longterm alternative fuel source to meet the city’s generation needs.

  • UK Rails’ first refurbished Class 395 Javelin re-enters passenger service with new seats and carpets, USB at-seat power sockets and LED lighting. Energy meters have also been installed to help reduce the energy and environmental impacts of the rail operator, Southeastern.

  • Australian Gas Networks’ Hydrogen Park South Australia features the largest electrolyser in  operation in Australia. By mid-2023, the number of premises to which blended renewable hydrogen is supplied has increased from 700 homes to nearly 4,000 homes and commercial properties.

  • CK Life Sciences presents promising preclinical data in liver cancer for its investigational dual-antigen cancer vaccine co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed deathligand 1) at the 2023 Society for Immunotherapy of Cancer Annual Meeting in San Diego, USA.

  • HUTCHMED’s in-house discovered drug FRUZAQLA™ (fruquintinib), for the treatment of colorectal cancer, is the company’s first US FDA approved medicine.

  • Hutchison Telecommunications Hong Kong Holdings upgrades its 5G sea coverage in  multiple hotspots in Hong Kong by deploying advanced hardware and software technologies  in the 700 MHz band of spectrum.

  • HUTCHMED’s new flagship manufacturing facility in Shanghai, China, completes construction and commences operations.